Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

被引：30
|
作者：
Barnes, Theresa [1 ]
Moots, Robert [1 ]
机构：
[1] Univ Liverpool, Acad Rheumatol, Liverpool L69 3BX, Merseyside, England
来源：
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2007年 / 2卷 / 01期
基金：
英国医学研究理事会;
关键词：
certolizumab pegol; TNF alpha; rheumatoid arthritis; nanomolecule;
D O I：
10.2147/nano.2007.2.1.3
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Anti-TNF alpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNF alpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNF alpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
引用
收藏
页码：3 / 7
页数：5
相关论文
共 50 条
  • [1] Certolizumab pegol for the treatment of rheumatoid arthritis
    Horton, Sarah
    Walsh, Ceara
    Emery, Paul
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (02) : 235 - 249
  • [2] Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)
    Dinesen, Lotte
    Travis, Simon
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (01): : 39 - 47
  • [3] Certolizumab pegol: a new biologic targeting rheumatoid arthritis
    Patel, Aarat M.
    Moreland, Larry W.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (06) : 855 - 866
  • [4] Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
    Connock, M.
    Tubeuf, S.
    Malottki, K.
    Uthman, A.
    Round, J.
    Bayliss, S.
    Meads, C.
    Moore, D.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 10
  • [5] Certolizumab Pegol In Rheumatoid Arthritis
    Duggan, Sean T.
    Keam, Susan J.
    [J]. BIODRUGS, 2009, 23 (06) : 407 - 417
  • [6] Certolizumab pegol in active rheumatoid arthritis
    Aarat M. Patel
    Larry W. Moreland
    [J]. Current Rheumatology Reports, 2009, 11 (5) : 311 - 312
  • [7] Optimisation of TNF-Inhibitor Therapy for Rheumatoid Arthritis: Focus on Certolizumab Pegol
    [J]. BioDrugs, 2014, 28 (Suppl 1) : 1 - 1
  • [8] Certolizumab Pegol Therapeutic Range in Rheumatoid Arthritis
    不详
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1278 - 1278
  • [9] Certolizumab pegol in rheumatoid arthritis: current update
    Fechtenbaum, Marie
    Yusof, Md Yuzaiful Md
    Emery, Paul
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (06) : 841 - 850
  • [10] Certolizumab pegol therapy of rheumatoid arthritis: Overview
    Zidi, Ines
    Mnif, Wissem
    Bouaziz, Aicha
    Ben Amor, Nidhal
    [J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (07) : 603 - 614
12345